Outlook Therapeutics’ (OTLK) Buy Rating Reiterated at Guggenheim

Guggenheim reiterated their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research report released on Friday morning,Benzinga reports. Guggenheim currently has a $12.00 target price on the stock.

Other analysts have also issued reports about the company. BTIG Research lowered their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 29th. Chardan Capital reiterated a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Outlook Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $28.07.

Outlook Therapeutics Price Performance

OTLK opened at $2.23 on Friday. The stock has a market capitalization of $55.55 million, a P/E ratio of -0.25 and a beta of 0.53. The company’s 50 day simple moving average is $2.70 and its 200-day simple moving average is $5.33. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06. As a group, analysts anticipate that Outlook Therapeutics will post -2.33 EPS for the current year.

Institutional Trading of Outlook Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC grew its holdings in Outlook Therapeutics by 677.4% during the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares during the period. Geode Capital Management LLC boosted its position in shares of Outlook Therapeutics by 49.2% during the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock worth $1,826,000 after purchasing an additional 112,812 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Outlook Therapeutics in the 3rd quarter valued at $199,000. State Street Corp increased its position in shares of Outlook Therapeutics by 10.0% in the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after buying an additional 21,201 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Outlook Therapeutics by 55.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock worth $275,000 after buying an additional 18,287 shares during the period. 11.20% of the stock is owned by institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.